Clincosm LogoSign in Get a demo

Evaluation of AP-002 in Patients With Solid Tumors

Sponsor
Altum Pharmaceuticals INC (Industry)
Overall Status
Unknown status
CT.gov ID
NCT04143789
Collaborator
(none)
61
Enrollment
3
Locations
1
Arm
18.1
Anticipated Duration (Months)
20.3
Patients Per Site
1.1
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The purpose of this trial is to define an effective and safe dose of AP-002 in advanced or recurrent solid tumors for which there are no standard therapies to use in subsequent studies in advanced or recurrent breast, non-small cell lung cancer (NSCLC) or prostate cancers.

Condition or Disease Intervention/Treatment Phase
Phase 1/Phase 2

Detailed Description

The Phase 1 portion of this study will determine the Pharmacodynamically Active Dose (PAD) of AP-002 in humans, defined as the dose at which the plasma concentration of AP-002, as measured by Ga, is 300-500 ng/mL and which is at or below the Maximum Tolerated Dose (MTD), to use in the clinical setting of advanced or recurrent solid tumors. This will be followed by a Phase 2 expanded cohort treated at the PAD, to estimate the efficacy of AP-002 in patients with advanced or recurrent breast cancer, NSCLC and prostate cancer.

Patients will receive AP-002 orally, once daily for 14 days of a 21 day cycle.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
61 participants
Intervention Model:
Sequential Assignment
Intervention Model Description:
Review of safety and pharmacokinetic (PK) parameters by the Clinical Trial Review Committee (CTRC) at the completion of each dose level in the Phase 1 will determine if escalation to the next dose level may occur. Anticipated Dose Levels in the Phase 1 Portion of the Study Cohort Anticipated Dose Anticipated Sample Size Level 1 8 mg QD PO × 14 days* (1 patient) Level 2 16 mg QD PO × 14 day* (1 patient) Level 3 32 mg QD PO × 14 days* (1 patient) Level 4 64 mg QD PO × 14 days* (1 patient) Level 5 84 mg QD PO × 14 days* (3 patients) Level 6 108 mg QD PO × 14 days* (3 patients) Level 7 140 mg QD PO × 14 days* (3 patients) Level 8 180 mg QD PO × 14 days* (3 patients) * Note: 21-day schedule with 2 weeks on, one week off. The actual sample size will be guided by the CRM; sample size may be larger for dose levels that require expansion. Interim meetings may occur when relevant new data becomes available between scheduled CTRC meetingsReview of safety and pharmacokinetic (PK) parameters by the Clinical Trial Review Committee (CTRC) at the completion of each dose level in the Phase 1 will determine if escalation to the next dose level may occur. Anticipated Dose Levels in the Phase 1 Portion of the Study Cohort Anticipated Dose Anticipated Sample Size Level 1 8 mg QD PO × 14 days* (1 patient) Level 2 16 mg QD PO × 14 day* (1 patient) Level 3 32 mg QD PO × 14 days* (1 patient) Level 4 64 mg QD PO × 14 days* (1 patient) Level 5 84 mg QD PO × 14 days* (3 patients) Level 6 108 mg QD PO × 14 days* (3 patients) Level 7 140 mg QD PO × 14 days* (3 patients) Level 8 180 mg QD PO × 14 days* (3 patients)Note: 21-day schedule with 2 weeks on, one week off. The actual sample size will be guided by the CRM; sample size may be larger for dose levels that require expansion. Interim meetings may occur when relevant new data becomes available between scheduled CTRC meetings
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
A Phase 1/2 Dose Escalation Study of AP-002 In Patients With Advanced or Recurrent Solid Tumors
Actual Study Start Date :
Sep 27, 2019
Anticipated Primary Completion Date :
Mar 1, 2021
Anticipated Study Completion Date :
Apr 1, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Tablets to be taken orally daily for 14 of 21 day cycle

AP-002 (4 mg and 20 mg tablets) to be taken orally daily for 14 days

Drug: AP-002
Dose escalation
Other Names:
  • no other names

    		•

    Outcome Measures

    Primary Outcome Measures

    1. Safety Assessment [Through study completion/ up to 18 months]

      Number of participants with treatment-related adverse events (safety and tolerability) as assessed by CTCAE v4.0

    2. Dose Assessment [Up to 6 months]

      Define the recommended phase 2 dose

    Secondary Outcome Measures

    1. Efficacy Assessment [Through study completion/ up to 18 months]

      Estimation of anti-tumor activity per RESIST v1.1

    2. Efficacy Assessment [Through study completion/ up to 18 months]

      For patients with bone metastases, the time to new bone metastasis, progression of bone metastases, or other skeletal related events

    3. Pharmacokinetic Assessment [Through study completion/ up to 18 months]

      Estimation of pharmacokinetic profile by evaluating maximum plasma concentration [Cmax]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:

    1. Phase 1: Patients with advanced or recurrent solid tumors with target (± non-target) or with only non-target disease, for which there is no standard therapy available Phase 2: Patients with advanced or recurrent breast cancer, NSCLC, or prostate cancer with target (± non-target) or with only non-target disease for which there is no standard therapy available

    2. Patients with bone metastases but without target disease are eligible

    3. Patients with bone metastases must have at least one bone lesion that has not received radiation therapy within 6 weeks prior to Cycle 1 Day 1

    4. Patients must discontinue bisphosphonate and/or denosumab treatment.

    5. Age ≥ 18 years

    6. Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

    7. O2 saturation ≥ 92% on room air per pulse oximetry

    8. Exhaled nitrous oxide ≤ 50 parts per billion (ppb)

    9. Adequate hematologic, hepatic and renal function defined as:

    10. Hemoglobin ≥ 9 g/dL

    11. Absolute neutrophil count (ANC) ≥ 1.5 × 109/L

    12. Platelet count ≥ 75 × 109/L

    13. Total bilirubin ≤ 2 × upper limit of normal (ULN). Patients with an established diagnosis of Gilberts syndrome with an unconjugated bilirubin ≤ 2 mg/dL and conjugated bilirubin within normal limits (WNL) are eligible.

    14. Serum electrolytes WNL

    15. Transaminases ≤ 3 × ULN

    16. Prothrombin time (PT)/international normalized ratio (INR), thromboplastin time (PTT), or activated PTT (aPTT) ≤ 1.5 × ULN. For patients on therapeutic coumadin, PT (INR) ≤ 2.5 × ULN is acceptable; for patients on therapeutic heparin, PTT (or aPTT) ≤ 2.5 × ULN

    17. Corrected creatinine clearance ≥ 40 mL/minute, based on the Cockcroft-Gault equation

    18. Patient must have discontinued prior antineoplastic therapy at least 21 days prior to Cycle 1 Day 1 and have recovered or stabilized from any prior AEs related to the prior therapy

    19. Provision of signed and dated informed consent form

    20. Serum 25-hydroxyvitamin D ≥ 30 ng/mL by investigative site laboratory at screening

    Exclusion Criteria:

    1. Evidence of benign primary hyperparathyroidism, hyperthyroidism, adrenal insufficiency, vitamin D intoxication, mild alkali syndrome, sarcoidosis or other granulomatous disease

    2. Treatment with calcitonin, mithramycin or cinacalcet within 7 days prior to the date of the screening

    3. Receiving dialysis for renal failure

    4. Patients with a known history of clinically significant active infection, including human immunodeficiency virus (HIV), hepatitis B, or hepatitis C

    5. Patients with active central nervous system (CNS) metastases are not eligible, but patients with treated, stable CNS metastases are allowed

    6. Patients with QT interval of ≥ 480 msec on ECG

    7. Patients with Paget's disease of bone

    8. Patients of childbearing potential unwilling to abstain from sexual intercourse, or employ effective barrier methods of contraception during participation in this trial

    9. Pregnancy or lactation. A negative pregnancy test will be required for women of childbearing potential prior to study enrollment and will be repeated throughout the study. Women of childbearing potential will be defined as women who have not had natural or pharmacologic menopause, nor surgical sterilization.

    10. Patients unwilling or unable to take oral medication, requiring a nasogastric or gastrostomy tube, or unwilling to adhere to the treatment regimen and fasting requirements

    11. Patients unwilling to comply with all study procedures or who are unavailable for the duration of the study

    12. Known allergies to any components of the AP-002 Drug Product

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Research Institution Chicago Illinois United States 60208
    2 Research Site Saint Louis Missouri United States 63110
    3 Investigational Site Houston Texas United States 77030

    Sponsors and Collaborators

    • Altum Pharmaceuticals INC

    Investigators

    • Study Chair: Angela Ogden, MD, Altum Pharmaceuticals

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Altum Pharmaceuticals INC
    ClinicalTrials.gov Identifier:
    NCT04143789
    Other Study ID Numbers:
    • ALT-002-SRE-01
    First Posted:
    Oct 29, 2019
    Last Update Posted:
    Oct 31, 2019
    Last Verified:
    Oct 1, 2019
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Additional relevant MeSH terms:
    Neoplasms

    Study Results

    No Results Posted as of Oct 31, 2019